第八版AJCC分期系统用于HPV相关口咽癌的验证
结果显示93.9%患者临床分期、91.7%患者病理分期发生变化,第八版临床与病理分期的生存一致性指数均较第七版改善,提示其生存区分能力提高。
要点
- 第八版分期使绝大多数HPV阳性口咽癌患者的分期发生改变
- 第八版临床与病理分期的生存一致性指数均优于第七版
- 第八版分期对HPV阳性口咽癌似有更好的生存区分能力
核心结论
- 第八版AJCC指南深刻改变了HPV阳性口咽癌的分期,并显示出改善的生存区分能力。
研究设计与样本
- 利用美国国家癌症数据库(NCDB)识别2010—2013年HPV阳性口咽癌患者,按第八版指南重新分期并与第七版比较,计算分期特异性总生存与一致性指数。
主要发现
- 临床分期发生改变者占93.9%,病理分期发生改变者占91.7%。
- 第八版临床分期生存一致性指数为0.621–0.656,病理分期为0.640–0.663,均较第七版改善。
临床怎么用
- 临床可参考第八版AJCC分期对HPV阳性口咽癌进行风险分层与预后判断。
- 重新分期后分期变化比例高,提示既往基于第七版分期的数据解读需注意版本差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The eighth edition American Joint Committee on Cancer (AJCC) staging manual includes major changes in staging of oropharyngeal cancer (OPC). We evaluated the new staging system in order to validate this shift in classification. METHODS: We used the National Cancer Database (NCDB) to identify patients with human papillomavirus-associated (HPV-positive) OPC from 2010-2013. We restaged patients using the eighth edition guidelines and compared them with those from the seventh edition. We calculated stage-specific overall survival and concordance indices. RESULTS: We identified 15 116 patients with a median follow-up period of 29.1 months. Clinical and pathological staging changed for 93.9% and 91.7% of patients, respectively. Survival concordance indices for both clinical (0.621-0.656) and pathological (0.640-0.663) staging were improved in the eighth edition compared to the seventh edition. CONCLUSION: The eighth edition guidelines have profoundly altered staging of HPV-positive OPC and seem to demonstrate improved survival discrimination.
引用
- Cramer JD, Hicks KE, Rademaker AW, et al. Validation of the eighth edition American Joint Committee on Cancer staging system for human papillomavirus-associated oropharyngeal cancer. Head Neck. 2017. PMID: 28990257. doi:10.1002/hed.24974
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。